Biblio
Export 2680 results:
Author Title Type [ Year
Filters: First Letter Of Keyword is A [Clear All Filters]
“Phonological and Semantic Fluency in Alzheimer's Disease: A Systematic Review and Meta-Analysis.”, J Alzheimers Dis, vol. 95, no. 1, pp. 1-12, 2023.
, “The PI3K/AKT Signaling Pathway and Caspase-3 in Alzheimer's Disease: Which One Is the Beginner?”, J Alzheimers Dis, vol. 92, no. 2, pp. 391-393, 2023.
, “The PI3K/AKT Signaling Pathway and Caspase-3 in Alzheimer's Disease: Which One Is the Beginner?”, J Alzheimers Dis, vol. 92, no. 2, pp. 391-393, 2023.
, “Plasma Glial Fibrillary Acidic Protein Is Associated with 18F-SMBT-1 PET: Two Putative Astrocyte Reactivity Biomarkers for Alzheimer's Disease.”, J Alzheimers Dis, vol. 92, no. 2, pp. 615-628, 2023.
, “Plasma Glial Fibrillary Acidic Protein Is Associated with 18F-SMBT-1 PET: Two Putative Astrocyte Reactivity Biomarkers for Alzheimer's Disease.”, J Alzheimers Dis, vol. 92, no. 2, pp. 615-628, 2023.
, “Plasma Glial Fibrillary Acidic Protein Is Associated with 18F-SMBT-1 PET: Two Putative Astrocyte Reactivity Biomarkers for Alzheimer's Disease.”, J Alzheimers Dis, vol. 92, no. 2, pp. 615-628, 2023.
, “Plasma Glial Fibrillary Acidic Protein Is Associated with 18F-SMBT-1 PET: Two Putative Astrocyte Reactivity Biomarkers for Alzheimer's Disease.”, J Alzheimers Dis, vol. 92, no. 2, pp. 615-628, 2023.
, “Plasma Soluble ST2 Levels Are Higher in Neurodegenerative Disorders and Associated with Poorer Cognition.”, J Alzheimers Dis, vol. 92, no. 2, pp. 573-580, 2023.
, “Playing Russian Roulette with Alzheimer's Disease Patients: Do the Cognitive Benefits of Lecanemab Outweigh the Risk of Edema, Stroke and Encephalitis?”, J Alzheimers Dis, vol. 92, no. 3, pp. 799-801, 2023.
, “Playing Russian Roulette with Alzheimer's Disease Patients: Do the Cognitive Benefits of Lecanemab Outweigh the Risk of Edema, Stroke and Encephalitis?”, J Alzheimers Dis, vol. 92, no. 3, pp. 799-801, 2023.
, “PM2.5 and Dementia in a Low Exposure Setting: The Influence of Odor Identification Ability and APOE.”, J Alzheimers Dis, vol. 92, no. 2, pp. 679-689, 2023.
, “PM2.5 and Dementia in a Low Exposure Setting: The Influence of Odor Identification Ability and APOE.”, J Alzheimers Dis, vol. 92, no. 2, pp. 679-689, 2023.
, “PM2.5 and Dementia in a Low Exposure Setting: The Influence of Odor Identification Ability and APOE.”, J Alzheimers Dis, vol. 92, no. 2, pp. 679-689, 2023.
, “Poor Oral Health as a Risk Factor for Dementia in a Swedish Population: A Cohort Study with 40 Years of Follow-Up.”, J Alzheimers Dis, vol. 92, no. 1, pp. 171-181, 2023.
, “Precision Medicine Approach to Alzheimer's Disease: Rationale and Implications.”, J Alzheimers Dis, vol. 96, no. 2, pp. 429-437, 2023.
, “Preventing Neurocognitive Decline in Adults Aging with HIV: Implications for Practice and Research.”, J Alzheimers Dis, vol. 95, no. 3, pp. 753-768, 2023.
, “Preventing Neurocognitive Decline in Adults Aging with HIV: Implications for Practice and Research.”, J Alzheimers Dis, vol. 95, no. 3, pp. 753-768, 2023.
, “Psychopharmacological Medication Use in Frontotemporal Dementia at the Time of Diagnosis: Comparison with Alzheimer's Disease.”, J Alzheimers Dis, vol. 95, no. 2, pp. 677-685, 2023.
, “Re-Addressing Dementia by Network Medicine and Mechanism-Based Molecular Endotypes.”, J Alzheimers Dis, vol. 96, no. 1, pp. 47-56, 2023.
, “Re-Addressing Dementia by Network Medicine and Mechanism-Based Molecular Endotypes.”, J Alzheimers Dis, vol. 96, no. 1, pp. 47-56, 2023.
, “Re-Addressing Dementia by Network Medicine and Mechanism-Based Molecular Endotypes.”, J Alzheimers Dis, vol. 96, no. 1, pp. 47-56, 2023.
, “Re-Addressing Dementia by Network Medicine and Mechanism-Based Molecular Endotypes.”, J Alzheimers Dis, vol. 96, no. 1, pp. 47-56, 2023.
, “Refining Risk for Alzheimer's Disease Among Heterozygous APOEɛ4 Carriers.”, J Alzheimers Dis, vol. 94, no. 2, pp. 483-489, 2023.
, “Refining Risk for Alzheimer's Disease Among Heterozygous APOEɛ4 Carriers.”, J Alzheimers Dis, vol. 94, no. 2, pp. 483-489, 2023.
, “Refining Risk for Alzheimer's Disease Among Heterozygous APOEɛ4 Carriers.”, J Alzheimers Dis, vol. 94, no. 2, pp. 483-489, 2023.
,